BIOMAT Database Logo BIOMAT Database Logo

Pharmacology of cis(Z)-clopenthixol decanoate, a depot neuroleptic. 1977

V Pedersen, and O Svendsen, and P Danneskiold-Samsoe, and V Boeck, and I M Nielsen

The duration and intensity of the neuroleptic effect of cis(Z)-clopenthixol decanoate in Viscoleo have been compared with those of cis(Z)-clopenthixol, 2 HCl in aqueous solution in a number of animal experimental models. Cis(Z)-clopenthixol, 2 HCl had a strong, but short-lasting neuroleptic effect (apomorphine antagonistic effect in dogs, inhibition of conditioned avoidance response in rats) which was accompanied by marked sedation. In contrast, cis(Z)-clopenthixol decanoate in oil had an effect which was slower in onset, but of much longer duration and only the highest doses caused a slight sedation. In rats catalepsy could be induced in some animals by high doses of cis(Z)-clopenthixol decanoate whereas cis(Z)-clopenthixol, 2 HCl at all the doses tested caused catalepsy in all animals. In mice only high doses of cis(Z)-clopenthixol decanoate in oil caused reduction of spontaneous motor activity and potentiation of barbiturate anaesthesia. The results are discussed with special reference to the clinical use of the depot preparation.

UI MeSH Term Description Entries
D007279 Injections, Subcutaneous Forceful administration under the skin of liquid medication, nutrient, or other fluid through a hollow needle piercing the skin. Subcutaneous Injections,Injection, Subcutaneous,Subcutaneous Injection
D008297 Male Males
D009043 Motor Activity Body movements of a human or an animal as a behavioral phenomenon. Activities, Motor,Activity, Motor,Motor Activities
D002375 Catalepsy A condition characterized by inactivity, decreased responsiveness to stimuli, and a tendency to maintain an immobile posture. The limbs tend to remain in whatever position they are placed (waxy flexibility). Catalepsy may be associated with PSYCHOTIC DISORDERS (e.g., SCHIZOPHRENIA, CATATONIC), nervous system drug toxicity, and other conditions. Cerea Flexibilitas,Flexibility, Waxy,Anochlesia,Anochlesias,Catalepsies,Flexibilitas, Cerea,Flexibilities, Waxy,Waxy Flexibilities,Waxy Flexibility
D003006 Clopenthixol A thioxanthene with therapeutic actions similar to the phenothiazine antipsychotics. It is an antagonist at D1 and D2 dopamine receptors. Cisordinol,Zuclopenthixol,alpha-Clopenthixol,alpha Clopenthixol
D003692 Delayed-Action Preparations Dosage forms of a drug that act over a period of time by controlled-release processes or technology. Controlled Release Formulation,Controlled-Release Formulation,Controlled-Release Preparation,Delayed-Action Preparation,Depot Preparation,Depot Preparations,Extended Release Formulation,Extended Release Preparation,Prolonged-Action Preparation,Prolonged-Action Preparations,Sustained Release Formulation,Sustained-Release Preparation,Sustained-Release Preparations,Timed-Release Preparation,Timed-Release Preparations,Controlled-Release Formulations,Controlled-Release Preparations,Extended Release Formulations,Extended Release Preparations,Slow Release Formulation,Sustained Release Formulations,Controlled Release Formulations,Controlled Release Preparation,Controlled Release Preparations,Delayed Action Preparation,Delayed Action Preparations,Formulation, Controlled Release,Formulations, Controlled Release,Prolonged Action Preparation,Release Formulation, Controlled,Release Formulations, Controlled,Sustained Release Preparation,Timed Release Preparation,Timed Release Preparations
D004285 Dogs The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065) Canis familiaris,Dog
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004353 Drug Evaluation, Preclinical Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications. Drug Screening,Evaluation Studies, Drug, Pre-Clinical,Drug Evaluation Studies, Preclinical,Drug Evaluations, Preclinical,Evaluation Studies, Drug, Preclinical,Evaluation, Preclinical Drug,Evaluations, Preclinical Drug,Medicinal Plants Testing, Preclinical,Preclinical Drug Evaluation,Preclinical Drug Evaluations,Drug Screenings,Screening, Drug,Screenings, Drug
D004357 Drug Synergism The action of a drug in promoting or enhancing the effectiveness of another drug. Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug

Related Publications

V Pedersen, and O Svendsen, and P Danneskiold-Samsoe, and V Boeck, and I M Nielsen
[cis(Z)-Clopenthixol decanoate--a new depot neuroleptic].
January 1982, International pharmacopsychiatry,
V Pedersen, and O Svendsen, and P Danneskiold-Samsoe, and V Boeck, and I M Nielsen
[Clinical experience with Cis-(Z-)Clopenthixol-Decanoate (Sordinol-Depot) (author's transl)].
November 1979, Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine Praxis,
V Pedersen, and O Svendsen, and P Danneskiold-Samsoe, and V Boeck, and I M Nielsen
[A new injectable delayed-action neuroleptic with sedative and antipsychotic action: cis-(Z)-clopenthixol decanoate. Clinical trials].
January 1984, L'Encephale,
V Pedersen, and O Svendsen, and P Danneskiold-Samsoe, and V Boeck, and I M Nielsen
Maintenance treatment of chronic schizophrenic patients. A study with the long-acting thioxanthene derivative, cis(Z)-clopenthixol decanoate-sordinol depot.
April 1978, Acta psychiatrica Scandinavica,
V Pedersen, and O Svendsen, and P Danneskiold-Samsoe, and V Boeck, and I M Nielsen
Haloperidol decanoate: a depot neuroleptic.
May 1983, Drug and therapeutics bulletin,
V Pedersen, and O Svendsen, and P Danneskiold-Samsoe, and V Boeck, and I M Nielsen
Serum concentrations of the isomers of clopenthixol and a metabolite in patients given cis(Z)-clopenthixol decanoate in viscoleo.
January 1983, Psychopharmacology,
V Pedersen, and O Svendsen, and P Danneskiold-Samsoe, and V Boeck, and I M Nielsen
Serum levels of the isomers of clopenthixol in patients given cis(Z)-clopenthixol or cis(Z)/trans(E)-clopenthixol.
January 1981, Acta psychiatrica Scandinavica. Supplementum,
V Pedersen, and O Svendsen, and P Danneskiold-Samsoe, and V Boeck, and I M Nielsen
Serum concentrations of cis(Z)- and trans(E)-clopenthixol after administration of cis(Z)-clopenthixol and clopenthixol to human volunteers.
January 1981, Acta psychiatrica Scandinavica. Supplementum,
V Pedersen, and O Svendsen, and P Danneskiold-Samsoe, and V Boeck, and I M Nielsen
The use of depot neuroleptic haloperidol decanoate.
February 1984, Acta psychiatrica Scandinavica,
V Pedersen, and O Svendsen, and P Danneskiold-Samsoe, and V Boeck, and I M Nielsen
Aspects of clinical psychiatric research on depot neuroleptics. The presentation of two double-blind trials with cis(z)-clopenthixol decanoate and a withdrawal study in schizophrenics.
January 1980, Acta psychiatrica Scandinavica. Supplementum,
Copied contents to your clipboard!